Metelimumab

Metelimumab is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a type of biopharmaceutical that is developed through recombinant DNA technology.

History[edit | edit source]

Metelimumab was developed by MedImmune, a subsidiary of AstraZeneca. The development of metelimumab is part of the broader trend of using monoclonal antibodies to treat autoimmune diseases, which has been a significant focus of biomedical research in the 21st century.

Mechanism of Action[edit | edit source]

As a monoclonal antibody, metelimumab works by binding to a specific target on the surface of cells. In the case of metelimumab, the target is a protein involved in the immune response. By binding to this protein, metelimumab can modulate the immune response and potentially alleviate the symptoms of autoimmune diseases.

Clinical Trials[edit | edit source]

Metelimumab has undergone several clinical trials to assess its safety and efficacy. These trials are a crucial part of the drug development process, and they involve testing the drug on a small number of healthy volunteers or patients. The results of these trials can determine whether the drug is approved for use in the general population.

Potential Uses[edit | edit source]

Metelimumab has potential uses in a variety of autoimmune diseases, including rheumatoid arthritis, psoriasis, and lupus. However, the drug is still in the early stages of development, and more research is needed to determine its effectiveness and safety in these conditions.